Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect ® MM Registry

Lisa La, Sundar Jagannath, MD, Sikander Ailawadhi, Brian G.M. Durie, MD, Cristina J. Gasparetto, MD, James W. Hardin, PhD, Hans C. Lee, MD, Mohit Narang, MD, James L. Omel, MD, Robert M. Rifkin, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, Lynne I. Wagner, PhD, Mazaher Dhalla, PharmD, Liang Liu, MS, Ling Yang, MS, Prashant Joshi, MD, Rafat Abonour, MD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-137309

Published: 2020

Journal Articles

Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect ® MM Registry

Hans C. Lee, MD, Sikander Ailawadhi, MD, Cristina Gasparetto, MD, Sundar Jagannath, Robert M. Rifkin, MD, Brian G.M. Durie, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, James W. Hardin, PhD, Lynne I. Wagner, PhD, James L. Omel, MD, Shankar Srinivasan, PhD MBA, Liang Liu, MS, Mazaher Dhalla, PharmD, Amit Agarwal, MD PhD, Rafat Abonour, MD

Blood (2019) 134 (Supplement_1): 3129.

https://doi.org/10.1182/blood-2019-126205

Published: 2019

Journal Articles

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Lynne I. Wagner, PhD, Kathleen Toomey, MD, Sikander Ailawadhi, MD, Sundar Jagannath, Cristina Gasparetto, MD, Brian G.M. Durie, MD, Mohit Narang, MD, Robert M. Rifkin, MD, Howard R. Terebelo, DO, James L. Omel, MD, James W. Hardin, PhD, Hans C. Lee, MD, Shankar Srinivasan, PhD MBA, Liang Liu, MS, Mazaher Dhalla, PharmD, Donna Catamero, ANP-BC, OCN, CCRC, Rafat Abonour, MD

Blood (2019) 134 (Supplement_1): 1843.

https://doi.org/10.1182/blood-2019-126143

Published: 2019

Journal Articles

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Robert M. Rifkin, MD, Jason M. Melear, MD, Edward Faber, DO, MS, William I. Bensinger, John M Burke, MD, Mohit Narang, MD, Don Stevens, MD, Sriya Gunawardena, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas S. Lin, MD PhD, Habte A Yimer, MD

Blood (2019) 134 (Supplement_1): 863.

https://doi.org/10.1182/blood-2019-122497

Published: 2019

Journal Articles

Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Habte Yimer, MD, Jason Melear, MD, Edward Faber, DO, MS, William Bensinger, MD, John M Burke, Mohit Narang, MD, Don Stevens, MD, Sriya W. Gunawardena, MD, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas Lin, MD PhD, Robert M Rifkin, MD

Blood (2018) 132 (Supplement 1): 152.

https://doi.org/10.1182/blood-2018-152

Published: 2018

Journal Articles

Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect ® MM Registry

Sundar Jagannath, MD, Mohit Narang, MD, Sikander Ailawadhi, Robert M Rifkin, MD, Howard R Terebelo, DO, Kathleen Toomey, MD, Brian GM Durie, MD, James W Hardin, PhD, Cristina J Gasparetto, MD, Lynne Wagner, PhD, James Omel, MD, Shankar Srinivasan, PhD MBA, Amani Kitali, MPH, MBA, Amit Agarwal, MD PhD, Rafat Abonour, MD

Blood (2018) 132 (Supplement 1): 3232.

https://doi.org/10.1182/blood-2018-99-110877

Published: 2018

Journal Articles

Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect ® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)

Mohit Narang, MD, Rafat Abonour, MD, Brian G. M. Durie, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, James W. Hardin, PhD, Sundar Jagannath, MD, Howard R. Terebelo, DO, Lynne Wagner, PhD, Shankar Srinivasan, PhD, E. Dawn Flick, MPH. ScD, Faiza Zafar, MPAS, Amani Kitali, MBA, MPH, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 3156.

https://doi.org/10.1182/blood.V130.Suppl_1.3156.3156

Published: 2017

Journal Articles

Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA (NAA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Connect ® MM Registry

Cristina J. Gasparetto, MD, Rafat Abonour, MD, Sundar Jagannath, MD, Brian G. M. Durie, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, James W. Hardin, PhD, Lynne Wagner, PhD, Shankar Srinivasan, PhD, Amani Kitali, MBA, MPH, E. Dawn Flick, MPH, Faiza Zafar, MPAS, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 3101.

https://doi.org/10.1182/blood.V130.Suppl_1.3101.3101

Published: 2017

Journal Articles

Development of a Predictive Model of Multiple Myeloma (MM) Patient (pt) Outcomes Based on Treatment Class Transitions Using the Connect ® MMpatient Registry

Sundar Jagannath, MD, Robert M. Rifkin, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, Brian G. M. Durie, MD, James W. Hardin, PhD, Howard R. Terebelo, DO, Lynne Wagner, PhD, Mohit Narang, MD, Shankar Srinivasan, PhD, Ahmed YoussefAgha, PhD, Amani Kitali, MBA, MPH, Gail Larkins, RN, MBA, Amit Agarwal, MD PhD, Rafat Abonour, MD

Blood (2017) 130 (Supplement 1): 3122.

https://doi.org/10.1182/blood.V130.Suppl_1.3122.3122

Published: 2017

Journal Articles

Development of a Prognostic Model That Predicts 3- and 5-Year Overall Survival in Multiple Myeloma Using the Connect ® MM Patient Registry

Howard R. Terebelo, DO, Rafat Abonour, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, Brian G. M. Durie, MD, James W. Hardin, PhD, Sundar Jagannath, MD, Lynne Wagner, PhD, Mohit Narang, MD, Shankar Srinivasan, PhD, Lihua Yue, PhD, Faiza Zafar, MPAS, Amani Kitali, MBA, MPH, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 1842.

https://doi.org/10.1182/blood.V130.Suppl_1.1842.1842

Published: 2017

Journal Articles

Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect ® MM Disease Registry

Rafat Abonour, MD, Brian G.M. Durie, MD, Sundar Jagannath, MD, Jatin J. Shah, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, James W. Hardin, PhD, Amani Kitali, MPH, PMP, Craig Gibson, PhD, Shankar Srinivasan, PhD, Arlene S. Swern, PhD, Robert M. Rifkin, MD

Blood (2016) 128 (22): 537.

https://doi.org/10.1182/blood.V128.22.537.537

Published: 2016

Journal Articles

Treatment Patterns from 2009 to 2015 in Patients with Newly Diagnosed Multiple Myeloma in the United States: A Report from the Connect ® MM Registry

Robert M. Rifkin, MD, Rafat Abonour, MD, Brian G.M. Durie, MD, Cristina J. Gasparetto, MD, Sundar Jagannath, MD, Mohit Narang, MD, Jatin J. Shah, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, Amani Kitali, MPH, PMP, Faiza Zafar, BSc, MBBS, Shankar Srinivasan, PhD, James W. Hardin, PhD

Blood (2016) 128 (22): 4489.

https://doi.org/10.1182/blood.V128.22.4489.4489

Published: 2016

Journal Articles

Connect MM®—the Multiple Myeloma (MM) Disease Registry: Incidence of Second Primary Malignancies (SPM)

Robert M. Rifkin, MD, Rafat Abonour, MD, Jatin J. Shah, MD, Jayesh Mehta, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Cristina J Gasparetto, MD, Sachdev P. Thomas, MD, Kathleen Toomey, MD, James W Hardin, PhD, Jane Jie Lu, MS, Laurie Kenvin, BSN, RN, Shankar Srinivasan, PhD, Rosanna J. Ricafort, MD, Yasir Nagarwala, MD, Brian G. M. Durie, MD

Blood (2014) 124 (21): 4749.

https://doi.org/10.1182/blood.V124.21.4749.4749

Published: 2014

Journal Articles

Connect MM ® —the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease

Jatin J. Shah, MD, Rafat Abonour, MD, Brian G M Durie, MD, Jayesh Mehta, MD, Mohit Narang, MD, Howard Terebelo, DO, Cristina J Gasparetto, MD, Sachdev P. Thomas, MD, Kathleen Toomey, MD, James W Hardin, PhD, Shankar Srinivasan, PhD, Rosanna J. Ricafort, MD, Yasir Nagarwala, MD, Robert M. Rifkin, MD

Blood (2014) 124 (21): 2106.

https://doi.org/10.1182/blood.V124.21.2106.2106

Published: 2014

Journal Articles

Response To First-Line Treatment In Stem Cell Transplant (SCT) and Non-SCT Patients With Newly Diagnosed Multiple Myeloma Who Are Enrolled In The Connect MM Registry

Rafat Abonour, MD, Jatin J. Shah, M.D., Brian Durie, MD, Howard Terebelo, DO, Cristina J Gasparetto, MD, Jayesh Mehta, MD, Mohit Narang, MD, Sachdev P Thomas, MD, Kathleen Toomey, MD, Kristen A Sullivan, MBA, CCRA, Shankar Srinivasan, PhD, Yasir Nagarwala, MD, Robert M Rifkin, MD

Blood (2013) 122 (21): 3207.

https://doi.org/10.1182/blood.V122.21.3207.3207

Published: 2013

Journal Articles

Association of Race with Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients

Chris L. Pashos, PhD, Brian GM Durie, MD, Robert Rifkin, MD, Howard Terebelo, DO, Cristina Gasparetto, MD, Jayesh Mehta, MD, Kathleen Toomey, MD, Rafat Abonour, MD, Rafael Fonseca, MD, Mohit Narang, MD, Jatin J Shah, MD, Arlene S Swern, PhD, Kristen A Sullivan, MBA, Thomas K. Street, RPh, Zeba M. Khan, PhD

Blood (2011) 118 (21): 5070.

https://doi.org/10.1182/blood.V118.21.5070.5070

Published: 2011

Journal Articles

Association of Changes in Transfusion Status with Changes in Health-Related Quality of Life of Real-World Patients with MDS Across Six Months of Treatment with Azacitidine

Chris L. Pashos, PhD, David L. Grinblatt, MD, Mikkael A. Sekeres, MD, MS, Rami S. Komrokji, MD, Mohit Narang, MD, Arlene S Swern, PhD, Thomas K. Street, RPh, Kristen A Sullivan, MBA, Gale Harding, MA, Zeba M. Khan, PhD

Blood (2011) 118 (21): 2796.

https://doi.org/10.1182/blood.V118.21.2796.2796

Published: 2011

Journal Articles

Variation in Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients by Insurance Coverage

Blood (2011) 118 (21): 3150.

https://doi.org/10.1182/blood.V118.21.3150.3150

Published: 2011

Journal Articles

Therapeutic Response to Azacitidine (AZA) In Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled In the AVIDA Registry

Mikkael A. Sekeres, MD, MS, Mohit Narang, MD, Rami S. Komrokji, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, Alan F. List, MD, Thomas K. Street, R.Ph, MBA, Arlene S. Swern, PhD, Kristen A. Sullivan, MBA, David L. Grinblatt, MD

Blood (2010) 116 (21): 2931.

https://doi.org/10.1182/blood.V116.21.2931.2931

Published: 2010

Journal Articles

New US Myeloma Registry (Connect MM® – The Multiple Myeloma Disease Registry): Features of Newly Diagnosed Patients In 2010

Brian G. M. Durie, MD, Jatin J. Shah, BS, MD, Rafat Abonour, MD, Cristina Gasperetto, MD, Jayesh Mehta, MD, Chris L. Pashos, PhD, Kathleen Toomey, MD, Mohit Narang, MD, Howard Terebelo, DO, Fernando Camacho, MD, Arlene S. Swern, PhD, Thomas K. Street, RPh, Kristen A. Sullivan, MBA, Robert M. Rifkin, MD

Blood (2010) 116 (21): 5032.

https://doi.org/10.1182/blood.V116.21.5032.5032

Published: 2010

NARROW

Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect ® MM Registry

Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect ® MM Registry

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect ® MM Registry

Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect ® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)

Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA (NAA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Connect ® MM Registry

Development of a Predictive Model of Multiple Myeloma (MM) Patient (pt) Outcomes Based on Treatment Class Transitions Using the Connect ® MMpatient Registry

Development of a Prognostic Model That Predicts 3- and 5-Year Overall Survival in Multiple Myeloma Using the Connect ® MM Patient Registry

Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect ® MM Disease Registry

Treatment Patterns from 2009 to 2015 in Patients with Newly Diagnosed Multiple Myeloma in the United States: A Report from the Connect ® MM Registry

Connect MM®—the Multiple Myeloma (MM) Disease Registry: Incidence of Second Primary Malignancies (SPM)

Connect MM ® —the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease

Response To First-Line Treatment In Stem Cell Transplant (SCT) and Non-SCT Patients With Newly Diagnosed Multiple Myeloma Who Are Enrolled In The Connect MM Registry

Association of Race with Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients

Association of Changes in Transfusion Status with Changes in Health-Related Quality of Life of Real-World Patients with MDS Across Six Months of Treatment with Azacitidine

Variation in Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients by Insurance Coverage

Therapeutic Response to Azacitidine (AZA) In Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled In the AVIDA Registry

New US Myeloma Registry (Connect MM® – The Multiple Myeloma Disease Registry): Features of Newly Diagnosed Patients In 2010

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only